ArticleBiomaterials2011
Bioreducible polymer-transfected skeletal myoblasts for VEGF delivery to acutely ischemic myocardium.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Poly(Amido Amine)s Containing Agmatine and Butanol Side Chains as Efficient Gene Carriers.Macromolecular bioscience · 2016Article
- Therapeutic angiogenesis promotes efficacy of human umbilical cord matrix stem cell transplantation in cardiac repair.Iranian journal of basic medical sciences · 2015Article
- Functional polymers of gene delivery for treatment of myocardial infarct.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Bioreducible polymers for therapeutic gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Improvements in biomaterial matrices for neural precursor cell transplantation.Molecular and cellular therapies · 2014Review
- Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia.Biomaterials · 2013Article
- Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier.Molecular pharmaceutics · 2013Article
- Therapeutic angiogenesis using genetically engineered human endothelial cells.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Biomaterials to gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
- Cells involved in extracellular matrix remodeling after acute myocardial infarction.Einstein (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Implantation of skeletal myoblasts to the heart has been investigated as a means to regenerate and protect the myocardium from damage after myocardial infarction. While several animal studies utilizing skeletal myoblasts have reported positive findings, results from clinical studies have been mixed. In this study we utilize a newly developed bioreducible polymer system to transfect skeletal myoblasts with a plasmid encoding vascular endothelial growth factor (VEGF) prior to implantation into acutely ischemic myocardium. VEGF has been demonstrated to promote revascularization of the myocardium following myocardial infarction. We report that implanting VEGF expressing skeletal myoblasts into acutely ischemic myocardium produces superior results compared to implantation of untransfected skeletal myoblasts. Skeletal myoblasts expressing secreted VEGF were able to restore cardiac function to non-diseased levels as measured by ejection fraction, to limit remodeling of the heart chamber as measured by end systolic and diastolic volumes, and to prevent myocardial wall thinning. Additionally, arteriole and capillary formation, retention of viable cardiomyocytes, and prevention of apoptosis was significantly improved by VEGF expressing skeletal myoblasts compared to untransfected myoblasts. This work demonstrates the feasibility of using bioreducible cationic polymers to create engineered skeletal myoblasts to treat acutely ischemic myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.